{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:31:00Z","timestamp":1794022260597,"version":"4.8.0"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M670675"],"award-info":[{"award-number":["2020M670675"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304291"],"award-info":[{"award-number":["82304291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173716"],"award-info":[{"award-number":["82173716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903789"],"award-info":[{"award-number":["81903789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejmech.2024.116547","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T23:12:49Z","timestamp":1717024369000},"page":"116547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity"],"prefix":"10.1016","volume":"275","author":[{"given":"Yaoguang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-3424","authenticated-orcid":false,"given":"Anhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116547_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116547_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib7","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","article-title":"Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy","volume":"10","author":"Chou","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116547_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","article-title":"CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib12","article-title":"Cyclin-dependent kinases in DNA damage response","volume":"1877","author":"Kciuk","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2024.116547_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-017-0611-1","article-title":"Cdk5 links with DNA damage response and cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib14","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.ejmech.2024.116547_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tips.2015.10.004","article-title":"Cyclin-dependent kinases as coregulators of inflammatory gene expression","volume":"37","author":"Schmitz","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116547_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.951202","article-title":"The role of Cdk5 in neurological disorders","volume":"16","author":"Ao","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2024.116547_bib17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tim.2021.01.014","article-title":"Cyclin-dependent kinases as emerging targets for developing novel antiviral therapeutics","volume":"29","author":"Gutierrez-Chamorro","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejmech.2024.116547_bib18","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (CDK) and their role in diseases development- review","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116547_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12935-022-02747-z","article-title":"A review on the role of cyclin dependent kinases in cancers","volume":"22","author":"Ghafouri-Fard","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2024.116547_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejmech.2017.08.071","article-title":"Structural insights of cyclin dependent kinases: implications in design of selective inhibitors","volume":"142","author":"Kalra","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib23","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1021\/acs.jmedchem.1c02190","article-title":"Lessons learned from past cyclin-dependent kinase drug discovery efforts","volume":"65","author":"Xie","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/13543776.2022.2078193","article-title":"A patent review of anticancer CDK2 inhibitors (2017-present)","volume":"32","author":"Said","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116547_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126637","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015\u20132019)","volume":"29","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116547_bib26","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib27","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/med.21769","article-title":"How selective are clinical CDK4\/6 inhibitors?","volume":"41","author":"Hendrychov\u00e1","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116547_bib28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21856","article-title":"Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline","volume":"42","author":"Bhurta","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116547_bib29","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib30","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1021\/acs.jmedchem.9b01985","article-title":"CDK7 inhibitors in cancer therapy: the sweet smell of success?","volume":"63","author":"Diab","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113043","article-title":"Angel or Devil ? - CDK8 as the new drug target","volume":"213","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib32","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 inh ibitors: an update","volume":"63","author":"Wu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib33","doi-asserted-by":"crossref","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","article-title":"Cyclin dependent kinase 9 inhibitors for cancer therapy","volume":"59","author":"Sonawane","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114603","article-title":"Current progress and novel strategies that target CDK12 for drug discovery","volume":"240","author":"Lei","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as antican cer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib36","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180112","article-title":"Structural insights into the functional diversity of the CDK-cyclin family","volume":"8","author":"Wood","year":"2018","journal-title":"Open Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib37","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.4161\/cc.9.8.11195","article-title":"Structural dissection of cyclin dependent kinases regulation and prote in recognition properties","volume":"9","author":"Lolli","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2024.116547_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/363595a0","article-title":"Crystal structure of cyclin-dependent kinase 2","volume":"363","author":"De Bondt","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116547_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1006\/jmbi.1999.2640","article-title":"Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors","volume":"287","author":"Pavletich","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.127.2.467","article-title":"Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase)","volume":"127","author":"Tassan","year":"1994","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/371254a0","article-title":"A cyclin associated with the CDK-activating kinase MO15","volume":"371","author":"M\u00e4kel\u00e4","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116547_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/376313a0","article-title":"Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex","volume":"376","author":"Jeffrey","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116547_bib43","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1021\/bi962349y","article-title":"Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism","volume":"36","author":"Heitz","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2024.116547_bib44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116547_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116547_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2015.4701","article-title":"Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development","volume":"2","author":"Clark","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2024.116547_bib47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116547_bib48","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116547_bib49","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116547_bib50","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116547_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib52","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3390\/cancers6042224","article-title":"Highlights of the latest advances in research on CDK inhibitors","volume":"6","author":"Cicenas","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116547_bib53","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.leukres.2014.06.007","article-title":"Orphan drug designation for pracinostat, volasertib and alvocidib in AML","volume":"38","author":"Bose","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/ml100051d","article-title":"Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases","volume":"1","author":"Paruch","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116547_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/jm201112g","volume":"55","author":"William","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib56","doi-asserted-by":"crossref","unstructured":"W.-G. Tong, R. Chen, W. Plunkett, D. Siegel, R. Sinha, R.D. Harvey, A.Z. Badros, L. Popplewell, S. Coutre, J.A. Fox, K. Mahadocon, T. Chen, P. Kegley, U. Hoch, W.G. Wierda, Phase I and pharmacologic study of SNS-032, a potent and selective cdk 2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma, J. Clin. Orthod., 28 3015-3022.","DOI":"10.1200\/JCO.2009.26.1347"},{"key":"10.1016\/j.ejmech.2024.116547_bib57","doi-asserted-by":"crossref","unstructured":"E.N. Scott, A.L. Thomas, L.R. Molife, S. Ahmed, S. Blagden, P.C. Fong, K. Kowal, C. McCoy, H. Wiesinger, W. Steward, J. De Bono, A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours, Cancer Chemother. Pharmacol., 64 425-429.","DOI":"10.1007\/s00280-009-0968-y"},{"key":"10.1016\/j.ejmech.2024.116547_bib58","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1021\/jm800382h","article-title":"Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design","volume":"51","author":"Wyatt","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib59","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/onc.2009.510","article-title":"AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition","volume":"29","author":"Santo","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116547_bib60","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1535-7163.MCT-09-1071","article-title":"AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples","volume":"9","author":"Squires","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116547_bib61","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","article-title":"The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group","volume":"58","author":"Seftel","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2024.116547_bib62","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1038\/bjc.2014.565","article-title":"A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177","volume":"111","author":"Chen","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib63","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/annonc\/mdq734","article-title":"A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors","volume":"22","author":"Mahadevan","year":"2011","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ejmech.2024.116547_bib64","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116547_bib65","doi-asserted-by":"crossref","unstructured":"D.S. Boss, G.K. Schwartz, M.R. Middleton, D.D. Amakye, H. Swaisland, R.S. Midgley, M. Ranson, S. Danson, H. Calvert, R. Plummer, C. Morris, R.D. Carvajal, L.R. Chirieac, J.H.M. Schellens, G.I. Shapiro, Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours, Ann. Oncol., 21 884-894.","DOI":"10.1093\/annonc\/mdp377"},{"key":"10.1016\/j.ejmech.2024.116547_bib66","series-title":"WO Patent","article-title":"Preparation of aminopyrazolylcyclopentyl carbamate derivatives for use as CDK2 inhibitors","author":"Behenna","year":"2020"},{"key":"10.1016\/j.ejmech.2024.116547_bib67","doi-asserted-by":"crossref","unstructured":"M. Sharma, B. Bashir, D. Juric, E.P. Hamilton, K.P. Papadopoulos, S.V. Ulahannan, G. Shapiro, V. Sahai, N.B. Mettu, M.M. Mita, M. Akce, J. Tao, G. Hodgson, N. Ke, S. Henry, S. Paul, N. Lodaya, C. Madigan, D.A. Roth, V. Klimek, Trial in progress: phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer, J. Clin. Orthod., 40 TPS4180-TPS4180.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4180"},{"key":"10.1016\/j.ejmech.2024.116547_bib68","doi-asserted-by":"crossref","unstructured":"U. L\u00fccking, A. Scholz, P. Lienau, G. Siemeister, D. Kosemund, R. Bohlmann, H. Briem, I. Terebesi, K. Meyer, K. Prelle, K. Denner, U. B\u00f6mer, M. Sch\u00e4fer, K. Eis, R. Valencia, S. Ince, F. von Nussbaum, D. Mumberg, K. Ziegelbauer, B. Klebl, A. Choidas, P. Nussbaumer, M. Baumann, C. Schultz-Fademrecht, G. R\u00fchter, J. Eickhoff, M. Brands, Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of cancer, ChemMedChem, 12 1776-1793.","DOI":"10.1002\/cmdc.201700447"},{"key":"10.1016\/j.ejmech.2024.116547_bib69","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1182\/blood-2017-07-793372","article-title":"CDK9 inhibition for ATL therapy","volume":"130","author":"Bazarbachi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116547_bib70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","article-title":"Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK 4\/6 inhibitors in ER+ breast cancer","volume":"6","author":"Al-Qasem","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejmech.2024.116547_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123566","article-title":"Combined CDK2 and CDK4\/6 inhibition overcomes palbociclib resistance in breast cancer by enhancing senescence","volume":"12","author":"Pandey","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116547_bib72","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib73","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ccell.2021.08.007","article-title":"Restoring order at the cell cycle border: Co-targeting CDK4\/6 and CDK2","volume":"39","author":"Jeselsohn","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib74","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/s41416-022-01990-5","article-title":"Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4\/6 inhibition in GIST","author":"Schaefer","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib75","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","article-title":"Discovery of PF-06873600, a CDK2\/4\/6 inhibitor for the treatment of cancer","volume":"64","author":"Freeman-Cook","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/jm501237k","article-title":"Exploring the scaffold universe of kinase inhibitors","volume":"58","author":"Hu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib77","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21856","article-title":"Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline","volume":"42","author":"Bhurta","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116547_bib78","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/cmdc.201300096","article-title":"The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer","volume":"8","author":"L\u00fccking","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116547_bib79","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib80","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.jmedchem.6b01254","article-title":"Cyclin-dependent kinase (CDK) inhibitors: structure-activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines","volume":"60","author":"Coxon","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114701","article-title":"Development and structure-activity relationship of tacrine derivatives as highly potent CDK2\/9 inhibitors for the treatment of cancer","volume":"242","author":"Wu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib82","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/jm301495v","article-title":"Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity","volume":"56","author":"Hole","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib83","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/jm301475f","article-title":"Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities","volume":"56","author":"Shao","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib84","doi-asserted-by":"crossref","first-page":"37305","DOI":"10.18632\/oncotarget.26468","article-title":"Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer","volume":"9","author":"Brisard","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116547_bib85","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acs.jmedchem.6b01670","article-title":"Highly potent, selective, and orally bioavailable 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation","volume":"60","author":"Tadesse","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib86","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1021\/acs.jmedchem.9b02121","article-title":"Discovery and SARs of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as oral available and dual CDK 6 and 9 inhibitors with potent antitumor activity","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib87","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: an overview of CDK\/inhibitor co-crystal structures","volume":"164","author":"Cheng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/jm401555v","article-title":"8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode","volume":"57","author":"Carbain","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nsb842","article-title":"Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor","volume":"9","author":"Davies","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib90","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ejca.2011.04.008","article-title":"Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301","volume":"47","author":"Thomas","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib91","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116547_bib92","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib93","doi-asserted-by":"crossref","first-page":"15200","DOI":"10.1002\/anie.201707630","article-title":"Lysine-targeting covalent inhibitors","volume":"56","author":"Pettinger","year":"2017","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib94","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chembiol.2015.07.018","article-title":"Identification and characterization of an irreversible inhibitor of CDK2","volume":"22","author":"Anscombe","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112424","article-title":"Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity","volume":"200","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib96","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4155\/fmc-2019-0062","article-title":"Development and strategies of CDK4\/6 inhibitors","volume":"12","author":"Chen","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib97","first-page":"26","article-title":"Development of CDK4\/6 inhibitors: a five years update","author":"Ammazzalorso","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116547_bib98","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116547_bib99","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2019.03.064","article-title":"Third-generation CDK inhibitors: a review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib","volume":"172","author":"Poratti","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113281","article-title":"Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors","volume":"215","author":"Lin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib101","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/ncomms7769","article-title":"CDK1 structures reveal conserved and unique features of the essential cell cycle CDK","volume":"6","author":"Brown","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib102","doi-asserted-by":"crossref","unstructured":"M. Zeng, J.M. Grandner, M.C. Bryan, V. Verma, R. Larouche-Gauthier, J.-P. Leclerc, L. Zhao, P. Haghshenas, S. Aubert-Nicol, A. Yadav, M. Ashley, J.Z. Chen, M. Durk, K.E. Samy, M. Nespi, E. Levy, K. Merrick, J.G. Moffat, J. Murray, A. Oh, C. Orr, E. Segal, J. Sims, C. Sneeringer, M. Prangley, S. Vartanian, S. Magnuson, B.T. Parr, Discovery of selective tertiary amide inhibitors of cyclin-dependent kinase 2 (CDK2), ACS Med. Chem. Lett., 14 1179-1187.","DOI":"10.1021\/acsmedchemlett.3c00142"},{"key":"10.1016\/j.ejmech.2024.116547_bib103","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/jm201112g","volume":"55","author":"William","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib104","doi-asserted-by":"crossref","unstructured":"Y. Yu, J. Huang, H. He, J. Han, G. Ye, T. Xu, X. Sun, X. Chen, X. Ren, C. Li, H. Li, W. Huang, Y. Liu, X. Wang, Y. Gao, N. Cheng, N. Guo, X. Chen, J. Feng, Y. Hua, C. Liu, G. Zhu, Z. Xie, L. Yao, W. Zhong, X. Chen, W. Liu, H. Li, Accelerated discovery of macrocyclic CDK2 inhibitor QR-6401 by generative models and structure-based drug design, ACS Med. Chem. Lett., 14 297-304.","DOI":"10.1021\/acsmedchemlett.2c00515"},{"key":"10.1016\/j.ejmech.2024.116547_bib105","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/acs.jmedchem.1c02069","article-title":"Discovery and optimization of highly selective inhibitors of CDK5","volume":"65","author":"Daniels","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/jm049323m","article-title":"Mechanism of CDK5\/p25 binding by CDK inhibitors","volume":"48","author":"Mapelli","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib107","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1016\/j.bmcl.2012.07.068","article-title":"Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)\/p25 inhibitors","volume":"22","author":"Malmstr\u00f6m","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116547_bib108","doi-asserted-by":"crossref","first-page":"48292","DOI":"10.1074\/jbc.M102034200","article-title":"The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism","volume":"276","author":"Clare","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib109","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.chembiol.2005.05.011","article-title":"Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation","volume":"12","author":"Ahn","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(92)90360-O","article-title":"Identification and properties of an atypical catalytic subunit (p34PSK-J3\/cdk4) for mammalian D type G1 cyclins","volume":"71","author":"Matsushime","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib111","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of selective kinase inhibitors","volume":"12","author":"Knight","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw2106","article-title":"p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition","volume":"366","author":"Guiley","year":"2019","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2024.116547_bib113","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1073\/pnas.0809645106","article-title":"Crystal structure of human CDK4 in complex with a D-type cyclin","volume":"106","author":"Day","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2024.116547_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127725","article-title":"Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells","volume":"33","author":"Shi","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116547_bib115","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1038\/s41467-021-26935-z","article-title":"Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation","volume":"12","author":"Kaltheuner","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib116","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1021\/acsmedchemlett.2c00408","article-title":"Discovery of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as highly selective CDK2 inhibitors","volume":"13","author":"Sokolsky","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116547_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114024","article-title":"Discovery of novel and orally bioavailable CDK 4\/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma","volume":"228","author":"Yuan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib118","doi-asserted-by":"crossref","first-page":"15102","DOI":"10.1021\/acs.jmedchem.2c00947","article-title":"Discovery, optimization, and evaluation of selective CDK4\/6 inhibitors for the treatment of breast cancer","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112239","article-title":"Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4\/6 inhibitors","volume":"193","author":"Shi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib120","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib121","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-Dependent transcriptional addiction in triple-negative breast cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib122","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cell.2015.09.013","article-title":"No driver behind the wheel? Targeting transcription in cancer","volume":"163","author":"Franco","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib123","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.molcel.2015.06.032","article-title":"THZ1 reveals roles for Cdk7 in co-transcriptional capping and pausing","volume":"59","author":"Nilson","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib124","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","article-title":"Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7","volume":"79","author":"Hu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113481","article-title":"Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12\/13 covalent inhibitor with efficacy in Ewing sarcoma","volume":"221","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib127","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1021\/acs.jmedchem.9b01929","article-title":"Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12\/13","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib128","doi-asserted-by":"crossref","first-page":"15770","DOI":"10.1021\/acs.jmedchem.2c01334","article-title":"Discovery of novel N-(5-(Pyridin-3-yl)-1 H-indazol-3-yl)benzamide derivatives as potent cyclin-dependent kinase 7 inhibitors for the treatment of autosomal dominant polycystic kidney disease","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"22","author":"Vervoort","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116547_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108229","article-title":"Targeting CDK7 in oncology: the avenue forward","volume":"240","author":"Li","year":"2022","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116547_bib131","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","article-title":"ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment","volume":"17","author":"Patel","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116547_bib132","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cmdc.201600535","article-title":"Inhibitor selectivity for cyclin-dependent kinase 7: a structural, the rmodynamic, and modelling study","volume":"12","author":"Hazel","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116547_bib133","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bpj.2020.12.030","article-title":"2.5 \u00c5-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942","volume":"120","author":"Greber","year":"2021","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2024.116547_bib134","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","article-title":"Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7","volume":"65","author":"Marineau","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib135","article-title":"Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7","volume":"263","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib136","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/13543776.2022.2126765","article-title":"A patent and literature review of CDK12 inhibitors","volume":"32","author":"Tang","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116547_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105501","article-title":"The reversible inhibitor SR-4835 binds Cdk12\/cyclin K in a noncanonical G-loop conformation","volume":"300","author":"Schmitz","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib138","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1016\/j.bmcl.2013.05.075","article-title":"Development of highly selective casein kinase 1\u03b4\/1\u03b5 (CK1\u03b4\/\u03b5) inhibitors with potent antiproliferative properties","volume":"23","author":"Bibian","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116547_bib139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cmdc.201700695","article-title":"Structure\u2010based design of selective noncovalent CDK12 inhibitors","volume":"13","author":"Johannes","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116547_bib140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib141","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1021\/acs.jmedchem.8b00683","article-title":"Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) inhibitors","volume":"61","author":"Ito","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib142","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1038\/ncomms4505","article-title":"The structure and substrate specificity of human Cdk12\/Cyclin K","volume":"5","author":"B\u00f6sken","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib143","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib144","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1021\/jm0605740","article-title":"4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects","volume":"49","author":"Kry\u0161tof","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib145","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/cb2004516","article-title":"The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508","volume":"7","author":"Baumli","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113244","article-title":"Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents","volume":"214","author":"Shao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib147","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib148","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jid.2020.12.035","article-title":"The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma","volume":"141","author":"Guhan","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2024.116547_bib149","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ejmech.2018.09.025","article-title":"Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib150","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","article-title":"Targeting CDK9 reactivates epigenetically silenced genes in cancer","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib151","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer","volume":"64","author":"L\u00fccking","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib152","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood.V128.22.289.289","article-title":"Selective targeting cyclin-dependent kinase-9 (CDK9) downmodulates c-MYC and induces apoptosis in diffuse large B-cell lymphoma (DLBCL) cells","volume":"128","author":"Rowland","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116547_bib153","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1021\/acs.jmedchem.1c01249","article-title":"Discovery of a series of 7-azaindoles as potent and highly selective CDK9 inhibitors for transient target engagement","volume":"64","author":"Barlaam","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114875","article-title":"Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors","volume":"244","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib155","doi-asserted-by":"crossref","unstructured":"T. Wu, B. Yu, Y. Xu, Z. Du, Z. Zhang, Y. Wang, H. Chen, L.A. Zhang, R. Chen, F. Ma, W. Gong, S. Yu, Z. Qiu, H. Wu, X. Xu, J. Wang, Z. Li, J. Bian, Discovery of selective and potent macrocyclic CDK9 inhibitors for the treatment of osimertinib-resistant non-small-cell lung cancer, J. Med. Chem., 66 15340-15361.","DOI":"10.1021\/acs.jmedchem.3c01400"},{"key":"10.1016\/j.ejmech.2024.116547_bib156","doi-asserted-by":"crossref","first-page":"12548","DOI":"10.1021\/acs.jmedchem.1c00271","article-title":"Discovery of N-(4-(3-isopropyl-2-methyl-2 H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a novel, potent, and oral cyclin-dependent kinase inhibitor against haematological malignancies","volume":"64","author":"Huang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114461","article-title":"Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies","volume":"238","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib158","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1021\/acs.jmedchem.3c02329","article-title":"Identification of a novel selective CDK9 inhibitor for the treatment of CRC: design, synthesis, and biological activity evaluation","volume":"67","author":"Zhong","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105875","article-title":"Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property","volume":"126","author":"Liu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib160","doi-asserted-by":"crossref","first-page":"19342","DOI":"10.1039\/D2NJ03667C","article-title":"Novel tacrine derivatives as potential CDK9 inhibitors with low cholin esterase inhibitory properties: design, synthesis, and biological evaluation","volume":"46","author":"Liu","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib161","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.1c01148","article-title":"Rational design and development of novel CDK9 inhibitors for the treat ment of acute myeloid leukemia","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib162","doi-asserted-by":"crossref","unstructured":"A. Richters, S.K. Doyle, D.B. Freeman, C. Lee, B.S. Leifer, S. Jagannathan, F. Kabinger, J.V. Koren, N.B. Struntz, J. Urgiles, R.A. Stagg, B.H. Curtin, D. Chatterjee, S. Mathea, P.J. Mikochik, T.D. Hopkins, H. Gao, J.R. Branch, H. Xin, L. Westover, G.C. Bignan, B.A. Rupnow, K.L. Karlin, C.M. Olson, T.F. Westbrook, J. Vacca, C.M. Wilfong, B.W. Trotter, D.C. Saffran, N. Bischofberger, S. Knapp, J.W. Russo, I. Hickson, J.R. Bischoff, M.M. Gottardis, S.P. Balk, C.Y. Lin, M.S. Pop, A.N. Koehler, Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors, Cell Chem. Biol., 28 (2021) 134-147.e114.","DOI":"10.1016\/j.chembiol.2020.10.001"},{"key":"10.1016\/j.ejmech.2024.116547_bib163","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P5-08-05","article-title":"Abstract P5-08-05: preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes","volume":"82","author":"Saffran","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib164","doi-asserted-by":"crossref","unstructured":"D.B. Freeman, T.D. Hopkins, P.J. Mikochik, J.P. Vacca, H. Gao, A. Naylor-Olsen, S. Rudra, H. Li, M.S. Pop, R.A. Villagomez, C. Lee, H. Li, M. Zhou, D.C. Saffran, N. Rioux, T.R. Hood, M.A.L. Day, M.R. McKeown, C.Y. Lin, N. Bischofberger, B.W. Trotter, Discovery of KB-0742, a potent, selective, orally bioavailable small molecule inhibitor of CDK9 for MYC-dependent cancers, J. Med. Chem., 66 15629-15647.","DOI":"10.1021\/acs.jmedchem.3c01233"},{"key":"10.1016\/j.ejmech.2024.116547_bib165","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/ncomms7769","article-title":"CDK1 structures reveal conserved and unique features of the essential cell cycle CDK","volume":"6","author":"Brown","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib166","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chembiol.2018.10.015","article-title":"Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition","volume":"26","author":"Wood","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib167","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/acs.jmedchem.2c00073","article-title":"Principles of kinase allosteric inhibition and pocket validation","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib168","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib169","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116547_bib170","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib171","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1517\/17460440802580106","article-title":"Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition","volume":"3","author":"Backes","year":"2008","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116547_bib172","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdt055","article-title":"Sorafenib: from literature to clinical practice","volume":"24","author":"Di Marco","year":"2013","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ejmech.2024.116547_bib173","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmb.2011.07.020","article-title":"The structure of CDK8\/CycC implicates specificity in the CDK\/cyclin family and reveals interaction with a deep pocket binder","volume":"412","author":"Schneider","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib174","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1021\/acsmedchemlett.6b00044","article-title":"Design and development of a series of potent and selective type II inhibitors of CDK8","volume":"7","author":"Bergeron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116547_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112443","article-title":"Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors","volume":"201","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib176","doi-asserted-by":"crossref","first-page":"13216","DOI":"10.1021\/acs.jmedchem.2c01042","article-title":"Design and synthesis of a 2-Amino-pyridine derivative as a potent CDK8 inhibitor for anti-colorectal cancer therapy","volume":"65","author":"Yan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib177","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1021\/acschembio.5b00398","article-title":"Type II inhibitors targeting CDK2","volume":"10","author":"Alexander","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib178","doi-asserted-by":"crossref","unstructured":"P. Brear, D. Ball, K. Stott, S. D'Arcy, M. Hyv\u00f6nen, Proposed allosteric inhibitors bind to the ATP site of CK2\u03b1, J. Med. Chem., 63 12786-12798.","DOI":"10.1021\/acs.jmedchem.0c01173"},{"key":"10.1016\/j.ejmech.2024.116547_bib179","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/cb100410m","article-title":"Discovery of a potential allosteric ligand binding site in CDK2","volume":"6","author":"Betzi","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib180","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1038\/s41467-023-38732-x","article-title":"Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding","volume":"14","author":"Faber","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib181","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1021\/acs.jmedchem.2c01731","article-title":"Screening through lead optimization of high affinity, allosteric cyclin-dependent kinase 2 (CDK2) inhibitors as male contraceptives that reduce sperm counts in mice","volume":"66","author":"Faber","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib182","doi-asserted-by":"crossref","unstructured":"D. Ni, S. Lu, J. Zhang, Emerging roles of allosteric modulators in the regulation of protein\u2010protein interactions (PPIs): a new paradigm for PPI drug discovery, Med. Res. Rev., 39 2314-2342.","DOI":"10.1002\/med.21585"},{"key":"10.1016\/j.ejmech.2024.116547_bib183","doi-asserted-by":"crossref","unstructured":"P.J. Cossar, P.J. Lewis, A. McCluskey, Protein\u2010protein interactions as antibiotic targets: a medicinal chemistry perspective, Med. Res. Rev., 40 469-494.","DOI":"10.1002\/med.21519"},{"key":"10.1016\/j.ejmech.2024.116547_bib184","doi-asserted-by":"crossref","unstructured":"M. Funamoto, Y. Sunagawa, M. Gempei, K. Shimizu, Y. Katanasaka, S. Shimizu, T. Hamabe-Horiike, G. Appendino, A. Minassi, A. Koeberle, M. Komiyama, K. Mori, K. Hasegawa, T. Morimoto, Pyrazole-curcumin suppresses cardiomyocyte hypertrophy by disrupting the CDK9\/CyclinT1 complex, Pharmaceutics, 14 1269.","DOI":"10.3390\/pharmaceutics14061269"},{"key":"10.1016\/j.ejmech.2024.116547_bib185","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.gendis.2021.06.005","article-title":"Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein\u2013protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells","volume":"9","author":"Cheng","year":"2022","journal-title":"Gene. Dis."},{"key":"10.1016\/j.ejmech.2024.116547_bib186","doi-asserted-by":"crossref","unstructured":"S.-S. Cheng, Y.-Q. Qu, J. Wu, G.-J. Yang, H. Liu, W. Wang, Q. Huang, F. Chen, G. Li, C.-Y. Wong, V.K.W. Wong, D.-L. Ma, C.-H. Leung, Inhibition of the CDK9\u2013cyclin T1 protein\u2013protein interaction as a new approach against triple-negative breast cancer, Acta Pharm. Sin. B, 12 1390-1405.","DOI":"10.1016\/j.apsb.2021.10.024"},{"key":"10.1016\/j.ejmech.2024.116547_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115858","article-title":"Design, synthesis, and biological evaluation of novel 4,4\u2032-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer","volume":"261","author":"Gao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib188","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.3390\/cancers14215388","article-title":"The renaissance of CDK inhibitors in breast cancer therapy: an update on clinical trials and therapy resistance","volume":"14","author":"Abdelmalak","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116547_bib189","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1021\/acs.jmedchem.0c00093","article-title":"Monomeric targeted protein degraders","volume":"63","author":"Hanan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib190","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","article-title":"Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate cancer","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114838","article-title":"A bibliometric analysis of PROTAC from 2001 to 2021","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib192","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.116547_bib193","doi-asserted-by":"crossref","unstructured":"M. Brand, B. Jiang, S. Bauer, K.A. Donovan, Y. Liang, E.S. Wang, R.P. Nowak, J.C. Yuan, T. Zhang, N. Kwiatkowski, A.C. M\u00fcller, E.S. Fischer, N.S. Gray, G.E. Winter, Homolog-selective degradation as a strategy to probe the function of CDK6 in AML, Cell Chem. Biol., 26 300-306.e309.","DOI":"10.1016\/j.chembiol.2018.11.006"},{"key":"10.1016\/j.ejmech.2024.116547_bib194","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib195","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1039\/C9CC00163H","article-title":"PROTACs suppression of CDK4\/6, crucial kinases for cell cycle regulation in cancer","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib197","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-selective degradation as a strategy to probe the function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib198","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bmcl.2019.03.035","article-title":"Selective degradation of CDK6 by a palbociclib based PROTAC","volume":"29","author":"Rana","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116547_bib199","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.chembiol.2019.03.005","article-title":"Targeted protein degradation for kinase selectivity","volume":"26","author":"Chamberlain","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4C RBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116547_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111952","article-title":"Development of selective mono or dual PROTAC degrader probe of CDK isoforms","volume":"187","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115342","article-title":"Bifunctional degraders of cyclin dependent kinase 9 (CDK9): probing the relationship between linker length, properties, and selective protein degradation","volume":"254","author":"Tokarski","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib203","doi-asserted-by":"crossref","first-page":"13865","DOI":"10.1002\/anie.202004087","article-title":"Development of CDK2 and CDK5 dual degrader TMX\u20102172","volume":"59","author":"Teng","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2024.116547_bib204","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","article-title":"Discovery of a first-in-class CDK2 selective degrader for AML differen tiation therapy","volume":"17","author":"Wang","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib205","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1021\/jm031145u","article-title":"3-Aminopyrazole inhibitors of CDK2\/cyclin A as antitumor agents. 1. Lead finding","volume":"47","author":"Pevarello","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib206","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib207","doi-asserted-by":"crossref","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer","volume":"64","author":"Wei","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib208","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.chembiol.2023.01.004","article-title":"Piperlongumine conjugates induce targeted protein degradation","volume":"30","author":"Pei","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib209","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging new concepts of degrader technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116547_bib210","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib211","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1021\/acs.jmedchem.2c02045","article-title":"Discovery of ll-K8-22: a selective, durable, and small-molecule degrader of the CDK8-cyclin C complex","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib212","doi-asserted-by":"crossref","first-page":"12877","DOI":"10.1021\/acs.jmedchem.3c00828","article-title":"Degradation of cyclin-dependent kinase 9\/cyclin T1 by optimized microtubule-associated protein 1 light chain 3 beta-recruiting coumarin analogs","volume":"66","author":"Zeng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib213","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-020-0620-z","article-title":"Prospecting for molecular glues","volume":"16","author":"den Besten","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib214","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1039\/D2CS00197G","article-title":"Chasing molecular glue degraders: screening approaches","volume":"51","author":"Domostegui","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116547_bib215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116547_bib216","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","article-title":"The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K","volume":"585","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116547_bib217","first-page":"93","article-title":"Design principles for cyclin K molecular glue degraders","author":"Kozicka","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116547_bib218","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.1c02184","article-title":"3,5,7-Substituted pyrazolo[4,3- d]Pyrimidine inhibitors of cyclin-dependent kinases and cyclin K degraders","volume":"65","author":"Jorda","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116547_bib219","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-020-16559-0","article-title":"Quantifying CDK inhibitor selectivity in live cells","volume":"11","author":"Wells","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116547_bib220","doi-asserted-by":"crossref","first-page":"9399","DOI":"10.1002\/anie.201302209","article-title":"Sulfoximines: a neglected opportunity in medicinal chemistry","volume":"52","author":"L\u00fccking","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2024.116547_bib221","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1021\/acschembio.6b00074","article-title":"Conformational adaption may explain the slow dissociation kinetics of roniciclib (BAY 1000394), a type I CDK inhibitor with kinetic selectivity for CDK2 and CDK9","volume":"11","author":"Ayaz","year":"2016","journal-title":"ACS Chem. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:24:19Z","timestamp":1720445059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424004276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":221,"alternative-id":["S0223523424004276"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116547","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116547"}}